Rozbor firmy
Roche (RHHBY): the Swiss pharmaceutical and diagnostics colossus
Key takeaways
- Roche is the only major player that combines pharma (drugs) and diagnostics (tests, instruments) under one roof at comparable scale.
- The diagnostics division creates a natural synergy with drugs — tests identify patients suitable for Roche therapies.
- The company faces a massive biosimilar wave that is eroding the market share of its formerly dominant oncology drugs.
- Roche is a traditional dividend payer, popular among European defensive investors.
- Through healthcare ETFs such as XDWH investors can gain Roche exposure without directly buying Swiss shares.
Roche is a Swiss company with a unique position in global healthcare: as the only major player that combines pharma and diagnostics at a comparable level. For an investor this means a different exposure than with pure pharmaceutical companies.
Two divisions, one synergy
Pharmaceuticals — prescription drugs, primarily oncology (Herceptin, Avastin, MabThera and their successors), neurology and immunology. Diagnostics — in-vitro diagnostics, instruments for hospital laboratories and test kits. The synergy is direct: a diagnostic test identifies the patient for whom the drug is indicated. So-called companion diagnostics reinforce therapeutic products.
Economic moat
Roche's moat is formed by the integrated model of drugs and diagnostics, depth of oncology pipeline and a strong scientific culture (Roche invests in R&D significantly above the sector average). The diagnostics division is more stable than pharma — hospital instruments are not replaced every year.
Biosimilars: the decade's greatest challenge
- Herceptin, Avastin and MabThera lost patent protection — biosimilars eroded their market share in the EU and US.
- Roche had to introduce successors — Phesgo, Tecentriq, Ocrevus — and it has managed this better than most analysts expected.
- Watch how the successors perform in clinical data and what their adoption rate among physicians is.
Dividend and ETF access
Roche is one of Europe's longest-running dividend growers — attractive to investors seeking stable dividend companies. Through sector ETFs such as XDWH you get Roche together with JNJ, Merck, AbbVie and other names in a single fund. Also look at the ETF overview for a comparison of available healthcare funds.
FAQ
Why does Roche have a diagnostics division alongside drugs?
Roche believes diagnostics and therapeutics reinforce each other — a test identifies patients for whom the drug is effective. This model improves treatment success, boosts drug adoption and gives the company data no one else has.
How can Roche be traded from the Czech Republic?
Roche trades on the Swiss exchange (SIX) as ROG and in the US as an ADR under the ticker RHHBY. Direct purchase is possible through a broker with access to those exchanges. A sector ETF holding Roche may be more convenient.
What are biosimilars and why do they threaten Roche?
Biosimilars are copies of biological drugs after patent expiry — similar to generics for chemical drugs. Roche lost market share in Herceptin and Avastin. The company was saved by having successors ready and by its diagnostics division remaining outside the reach of biosimilars.